Inhibition of micrometastatic prostate cancer cell spread in animal models by213bilabeled multipletargeted α radioimmunoconjugates

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 865-875

  Li, Yong ^a,c   Song, Emma ^a,c   Rizvi, Syed M Abbas ^a   Power, Carl A ^a,b   Beretov, Julia ^a   Raja, Chand ^c   Cozzi, Paul J ^a   Morgenstern, Alfred ^d   Apostolidis, Christos ^d   Allen, Barry J ^a,c   Russell, Pamela J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BLCA 38 ANTIGEN; MONOCLONAL ANTIBODY BI 213; MUCIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2 BI 213; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UROKINASE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCONJUGATES; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOISOTOPES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 61349165644     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1203     Document Type: Article

References (44)

1. Carroll PR, Kantoff PW, Balk SP, et al. Overview consensus statement: newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60:1-6.
2. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-41.
3. Soerdjbalie-Maikoe V, Pelger RCM, Lycklama à Nijeholt GA, et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med 2002;29:494-8.
4. Beer TM, El-Geneidi M, Eilers KM. Docetaxel (Taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 2003;3:261 -8.
5. Tannock IF, Wit RD, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Sgouros G, Ballangrud AM, JurcicJG, et al. Pharmacokinetics and dosimetry of an α-particle emitter labelled antibody: 213Bi-Hu M 195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46.
7. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095 -100.
8. McDevitt MR, MaD,Lai LT,et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40.
9. Wang J, Abbas Rizvi SM, Madigan MC, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted a radioimmunoconjugates. Prostate 2006;66:1753-67.
10. Li Y, Rizvi SMA,Brown JM,et al. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095 -100. Biconjugates. Int J Radiat Oncol Biol Phys 2004;60:896-908.
11. Cozzi PJ, Wang J, Delprado W, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005;22:565-73.
12. 213Bi-C595 radioimmunoconjugate. Br J Cancer 2004;91:2086-93.
13. Russell PJ, Ow KT, Tam PN, et al. Immunohisto-chemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer. Cancer Immunol Immunother 2004;53:995-1004.
14. Cozzi PJ,Wang J, Delprado W, Madigan MC, Russell PJ, Li Y. Expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) in the progression of prostate cancer: Potential therapeutic targets. Human Pathol 2006;37:1442-51.
15. Yamamoto M, Sawaya R, Mohanam S. Activities, localization, and roles of serine proteases and their inhibitors in human brain tumor progression. J Neuro Oncol 1994;22:139-51.
16. Mustjoki S, Alitalo R, Stephens RW,Vaheri A. Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 1999;107:144-9.
17. Schmitt M,Wilhelm OG, Reuning U, et al.The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol & Proteol 2000;14:114-32.
18. Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type 2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res 2004;297:259-71.
19. Kruithof EKO, Baker MS, Bunn CL. Biochemistry, cellular and molecular biology and clinical aspects of plasminogen activator inhibitor type-2. Blood 1995; 86:4007-27.
20. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002;86:1197 -230.
21. Allen BJ,Tian Z, Rizvi SMA, Li Y, Ranson M. Preclinical studies of targeted αaherapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. BrJ Cancer 2003;88:944-50.
22. Gleave M, Hseih JT, Gao C, von Eschenbach AC, Chung LKW. (1991) Acceleration of human prostate cancer in vivo by factors produced by prostate and bione fibroblasts. Cancer Res1991;51:3753 -61.
23. Corey E, Quinn JE,Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 2003;56:110-4.
24. Corey E, Quinn JE, Bladou F, et al. Establishment and characterization of osseous prostate cancer models: intratibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
25. Fisher JL, Schmitt JF, Howard ML, Mackie PS, Choong PFM, Risbridger GP. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res 2002;307:337 -45.
26. ApostolidisC, Molinet, R, Rasmussen, G, Morgenstern A. Production of Ac-225 from Th-229 for targeted αtherapy. Anal Chem 2005;7:6288-91.
27. Perry MC. Chemotherapy source book. Philadelphia: LippincottWilliams& Wilkins; 2001.
28. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119: 493-501.
29. Flanigan RC, Shankey TV. The natural history of human prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, editors. Principles of Genitourinary Oncology, Philadelphia: Lippincott-Raven; 1997. p. 443 -50.
30. Ware JL, Paulson DF, Mickey GH, WebbKS. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 1982;128:1064-7.
31. Jain RK. (1991) Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991;60:85-100.
32. Hoffman RM. Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models?. J Cell Biochem 1994;56:1-3.
33. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997;31:168-74.
34. Abbas Rizvi SM, Li Y, Song EY, et al. Preclinical studies ofbismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther 2006;5:386-93.
35. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
36. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655 -64.
37. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer1998;77:887-94.
38. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radio- biology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res1992;130:220-6.
39. Russell PJ, Hewish D, Carter T, et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother 2004;53:411 -21.
40. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol CancerTherapy 2002;1:553-63.
41. 213Bi-immunoconjugates in HSC45 -2 gastric cancer cells is different from apoptotic cell death. EurJNucl Med Mol Imaging 2005;32:274-85.
42. Pouget JP, Mather SJ. General aspects of the cellular response to low- and high-LETradiation. Eur J Nucl Med 2001;28:541 -61.
43. Shao C, Furusawa Y, Kobayashi Y, FunayamaT, Wada S. Bystander effect induced by counted high-LETparticles in confluent human fibroblasts: a mechanistic study. FASEB J 2003;17:1422 -7.
44. Wang R, Coderre JA. A bystander effect in α-particle irradiations of human prostate tumor cells. Radiation Res 2005;164:711-22.